The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).

Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, wh ...

These White House deals will require the nine midsize pharma companies to provide MFN prices to state Medicaid programmes nationally.

The Australia-based STAREE trial is the first of its kind demonstrating the preventative effects of statins in older patients.

ReviR Therapeutics has received a RPDD from the US FDA for RTX-117, its investigational oral small-molecule therapy for CMT.

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B.

Priovant is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies.

The US FDA has approved ViiV Healthcare’s Tivicay PD, for use with other antiretroviral agents in paediatric patients with HIV-1 who weigh at least 2 kg.

Revolution Medicines’ breakthrough drug for pancreatic cancer was approved more than six months ahead of schedule.

Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.

The myasthenia gravis (MG) market across the 7MM is poised to grow at a CAGR of 11.1% from $4.5bn in 2024 to $13.0bn in 2034.